Niagen. BIOSCIENCE

NEWS RELEASE

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

2026-10-22

Liquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade **Niagen™ At-Home Injection Kit**, featuring the Company's first ready-to-inject liquid formulation with **Niagen™** (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available, now available through its **Niagen™ Plus** telehealth platform.

Liquid formulation of Niagen Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

NAD+ injections are increasingly available, yet no published clinical studies have evaluated subcutaneous (sub-q) or intramuscular (IM) NAD+ injections. In contrast, Niagen Bioscience published two pilot clinical studies of sub-q and IM Niagen injections on medRxiv. In these open-label pilot studies, injectable Niagen was well tolerated, including over 90 days of at-home use. Exploratory, self-reported outcomes were associated with reduced fatigue and improved sleep and skin. These findings require confirmation in larger, placebo-controlled studies (**Nkrumah-Elie et al., 2026**; **Russ et al., 2026**).

"The liquid Niagen At-Home Injection Kit is a meaningful step in building Niagen Plus into a scalable telehealth platform," said Rob Fried, Chief Executive Officer of Niagen Bioscience. "Additionally, telehealth partners are central to how we intend to scale Niagen Plus. We believe a ready-to-inject format with fewer steps, backed by new pilot clinical data, provides a superior product for telehealth partners, extending reach beyond our own direct-to-patient

channel."

Each kit includes a sterile, multi-dose 5 mL vial with 500 mg of Niagen, syringes, and alcohol prep pads. Patients simply draw the clinician-prescribed dose and inject subcutaneously: fewer components, fewer steps. The program remains clinician-directed and prescription-only. Patients complete an online intake form, a licensed provider decides whether to prescribe, and if prescribed, the medication is dispensed from state-licensed 503A compounding pharmacies and shipped to their door. NiagenPlus.com is LegitScript Certified, an independent third-party certification for healthcare merchants and telehealth platforms.

Study Highlights

Two open-label pilot studies evaluated the safety and tolerability of injectable Niagen in 39 generally healthy adults with elevated fatigue (**Nkrumah-Elie et al., 2026**; **Russ et al., 2026**). Participants were randomized to 50 mg or 100 mg of Niagen by IM or sub-q injection for three days under clinical supervision, then self-administered subcutaneous Niagen at home three times weekly for an additional 90 days. Building on the safety data, these pilot studies also feature the first exploratory findings on IM and sub-q Niagen injections.

Findings:

- Three days of supervised injections followed by 90 days of self-injection were well tolerated with no unexpected adverse events reported.
- At-home sub-q self-administered Niagen injections were achievable under protocol-defined conditions, supporting the feasibility of at-home administration.
- Blood NAD+ levels remained stable over the 90 days.
- Repeated Niagen injections were associated with improvements in fatigue, sleep impairment (e.g., daytime sleepiness), and quality of life, as assessed using validated participant-reported outcome questionnaires, as well as self-reported improvements in skin health.
- The study observed changes in markers of mitochondrial bioenergetics (efficient cellular energy production) and reductions in several oxidative stress markers (less cellular wear and tear). Because the study was open-label and not placebo-controlled, these findings are exploratory and require confirmation.

More on these findings can be found on **www.aboutnad.com** in the following blog posts: **Nicotinamide Riboside Injections: What Two New Pilot Studies Reveal About Safety** and **Nicotinamide Riboside Injections: Exploratory Findings from a Two-Part Pilot Study**.

For additional information on liquid Niagen At-Home Injection Kit, visit **www.niagenplus.com**.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at **www.truniagen.com**), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (**www.niagenplus.com**). Pharmaceutical-grade Niagen™ IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at **www.niagenbioscience.com**, where copies of press releases, news, and financial information are regularly published.

† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Niagen Bioscience, Inc. ("Niagen Bioscience" or the "Company") intends these statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. These include statements about the Company's

strategy, plans, objectives, expectations, and intentions; the development, regulatory status, launch, and commercial success of its products and product candidates; the design, timing, and results of preclinical and clinical studies; the scaling of its Niagen™ Plus platform and telehealth partnerships; its intellectual property position; and its future financial and operating results. Forward-looking statements can often be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would,” or the negative of these terms or similar expressions. The absence of these words does not mean a statement is not forward-looking.

Forward-looking statements are based on management’s current expectations, estimates, and assumptions. They are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, the following:

Regulatory risks. These include risks related to the regulation of the Company’s products by the U.S. Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), state boards of pharmacy, and comparable foreign authorities. They include the Company’s ability to maintain the regulatory status of nicotinamide riboside (“NR”) as a dietary ingredient, including under its New Dietary Ingredient notifications and Generally Recognized as Safe determinations. They include the Company’s ability to keep NR on the FDA’s list of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Category 1), and the eligibility of NR for compounding under Section 503A. They include changes in FDA policy, guidance, or enforcement priorities for compounded drugs, dietary supplements, or NAD+ precursors. They also include the risk that the FDA, the FTC, or state regulators find the Company’s product claims, labeling, or marketing inadequately substantiated or otherwise noncompliant.

Pharmaceutical development and clinical risks. These include risks related to the NB4168 development program of NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary. They include the timing, cost, and outcome of planned preclinical, IND-enabling, and clinical activities, and the timing of any Investigational New Drug application or first-in-human study. They include the risk that NB4168 or any other product candidate fails to show adequate bioavailability, exposure, safety, tolerability, efficacy, or pharmacodynamic activity. They include the ability to enroll enough subjects in clinical trials, and the risk that results of preclinical, pilot, open-label, or early-stage studies will not be replicated in larger, controlled trials. They include the risk that clinical or scientific data, including data published as preprints that have not been peer-reviewed, will be interpreted differently by regulators, the scientific community, or the market. They also include the risk that the Company will be unable to obtain marketing approval for any pharmaceutical product, or will obtain approval only for limited indications.

Commercial and competitive risks. These include the growth and profitability of the Company’s product sales and

its ability to maintain and grow its sales, marketing, and distribution capabilities. They include the commercial success of Tru Niagen in consumer channels, including e-commerce marketplaces, and of Niagen Plus pharmaceutical-grade intravenous and injectable products. They include the Company's reliance on third-party clinics, licensed prescribers, telehealth partners, and pharmacies, and its ability to obtain and keep appropriate contracts with FDA-registered 503B outsourcing facilities and state-licensed 503A pharmacies. They include the effect of state laws on telehealth, the corporate practice of medicine, and remote prescribing. They also include competition from other NAD+ precursors, compounded NAD+ products, and dietary supplements, including products that may be mislabeled, adulterated, or marketed with unsubstantiated claims, and changing consumer and clinician perceptions of the Company's products and of NAD+ science generally.

Intellectual property risks. These include the Company's ability to maintain, defend, and enforce its existing patents and other intellectual property, and to obtain new patents covering NR, other NAD+ precursors, formulations, and methods of use. They include the expiration of key patents, challenges to the validity or enforceability of the Company's patents, the risk of infringement claims by third parties, and the cost and uncertainty of intellectual property litigation.

Manufacturing and supply chain risks. These include the Company's reliance on a single or limited number of third-party suppliers and manufacturers, including suppliers located in China, and its ability to secure adequate quantities of dietary-grade and pharmaceutical-grade Niagen® in a timely manner and to required quality standards. They include risks of product contamination, recalls, or quality failures. They also include the effect of tariffs, trade restrictions, export controls, and geopolitical developments on the Company's costs and supply.

Financial and general risks. These include the Company's history of operating losses and its ability to achieve and sustain profitability. They include its future capital requirements, including to fund pharmaceutical development, and the availability of financing on acceptable terms or at all, which could result in dilution to stockholders. They include the Company's ability to continue to meet Nasdaq listing requirements, product liability and other litigation, inflation and adverse economic or market conditions, and the Company's ability to attract and retain key personnel.

These and other risks and uncertainties are described in more detail under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission ("SEC"), including its most recent Annual Report on Form 10-K and later Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available on the SEC's website at **www.sec.gov** and in the Investors section of the Company's website at **www.niagenbioscience.com**. The risks described above are not exhaustive. New risks emerge from time to time, and the Company cannot predict all risks or assess their impact on its business.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are expressly qualified in their entirety by this cautionary

statement. Except as required by applicable law, Niagen Bioscience™ undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changes in assumptions, or otherwise.

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Niagen@kcsa.com

Source: Niagen Bioscience, Inc